Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence

Pituitary

Volumn 16, Issue 3, 2013, Pages 370-377

  Sánchez Ortiga, Ruth ^a   Sánchez Tejada, Laura ^a   Moreno Perez, Oscar ^a   Riesgo, Pedro ^b   Niveiro, Maria ^a   Picó Alfonso, Antonio M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b Ribera's Hospital   (Spain)

Author keywords

KDR Tyrosine kinase; Pituitary adenoma; Recurrence; VEGF

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; MESSENGER RNA; SOMATOSTATIN DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; MALE; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR GROWTH; VEGF GENE;

EID: 84881369135     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0434-4     Document Type: Article

References (27)

1. Turner HE, Harris AL, Melmed S, Wass JA (2003) Angiogenesis in endocrine tumors. Endocr Rev 24(5):600-632
2. Kurosaki M, Saeger W, Abe T, Ludecke DK (2008) Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res. doi: 10.1179/174313208X289499
3. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87(9):4238-4244
4. Niveiro M, Aranda FI, Peiro G, Alenda C, Pico A (2005) Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol 36(10):1090-1095. doi: 10.1016/j.humpath.2005.07.015
5. Raica M, Coculescu M, Cimpean AM, Ribatti D (2010) Endocrine gland derived-VEGF is down-regulated in human pituitary adenoma. Anticancer Res 30(10):3981-3986
6. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676. doi: 10.1038/nm0603-669
7. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA (2000) Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85(3):1159-1162
8. Kerbel RS, Viloria-Petit A, Okada F, Rak J (1998) Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4(5):286-295
9. Ferrara N (2000) Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55:15-35 (discussion 35-16)
10. Risau W (1997) Mechanisms of angiogenesis. Nature 386(6626):671-674. doi: 10.1038/386671a0
11. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161(2):851-858
12. Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK, Matsutani M (1998) Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol 96(5):453-462
13. Fukui S, Otani N, Nawashiro H, Yano A, Nomura N, Tokumaru AM, Miyazawa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Shima K, Ooigawa H (2003) The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma. J Clin Neurosci 10(3):320-324
14. Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM (2003) The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol 148(2):203-211
15. Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I, Genovesi M, Martino E (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26(1):23-28
16. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L (1999) Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10(3):229-235
17. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC (1998) Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4(12):3017-3024
18. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963-969
19. Borg SA, Kerry KE, Royds JA, Battersby RD, Jones TH (2005) Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells. Eur J Endocrinol 152(2):293-300. doi: 10.1530/eje.1.01843
20. Cristina C, Perez-Millan MI, Luque G, Dulce RA, Sevlever G, Berner SI, Becu-Villalobos D (2010) VEGF and CD31 association in pituitary adenomas. Endocr Pathol 21(3):154-160. doi: 10.1007/s12022-010-9119-6
21. Iuchi T, Saeki N, Osato K, Yamaura A (2000) Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien) 142(12):1345-1351
22. Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK, Renner U (2006) Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. J Endocrinol 191(1):249-261
23. Pan LX, Chen ZP, Liu YS, Zhao JH (2005) Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol 74(1):71-76. doi: 10.1007/s11060-004-6150-9
24. Yarman S, Kurtulmus N, Canbolat A, Bayindir C, Bilgic B, Ince N (2010) Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior? Neuro Endocrinol Lett 31(6):823-828
25. Lawnicka H, Pisarek H, Kunert-Radek J, Pawlikowski M (2008) Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro. Neuro Endocrinol Lett 29(1):113-116
26. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14(1):91-102
27. Taboada GF, Luque R, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65-74